September 23, 2005 -- Side effects forced Genentech to stop enrolling patients in an Avastin trial among patients with relapsed ovarian cancer, Biomira announced positive data from a lung cancer trial and pushed back trials for the next phase of testing, Flamel said its hepatitis C treatment cut side effects while maintaining the same level of efficacy, Renovis placed 4 million shares at $13.50, GTx delayed a 5 million share offering because of market conditions, and Sunesis Pharma did not price its IPO, which was scheduled for this week. Helped by the $2.3 billion loss of market capitalization in Genentech today, the Centient Biotech 200 dropped 17 points to end at 3806, a loss of .46%. More details...
